US stock · Healthcare sector · Diagnostics & Research
Company Logo

Agilent Technologies, Inc.

ANYSE

155.69

USD
-0.54
(-0.35%)
Market Closed
37.38P/E
25Forward P/E
1.88P/E to S&P500
46.095BMarket CAP
0.54%Div Yield
Upcoming Earnings
20 Feb-24 Feb
Shares Short
1/13/23
3.37M
Short % of Float
1.14%
Short % of Shares Outs.
1.14%
% Held by Insiders
0.24%
% Held by Institutions
89.95%
Beta
1.06
PEG Ratio
2.31
52w. high/low
160.26/112.52
Avg. Daily Volume
1.31M
Return %
Stock
S&P 500
1 year
15.24
(8.28)
3 years
75.96
21.43
5 years
109.89
40.45
Scale: |
High
Low
27.18
10.56
22.73
8.60
30.10
19.08
39.58
20.51
33.10
25.26
41.44
28.75
43.79
35.62
43.59
33.12
48.63
34.15
70.93
45.74
75.11
60.42
85.68
62.00
120.24
61.13
179.57
112.47
160.26
112.52
159.59
143.01
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
13.76
15.91
12.95
15.69
19.06
19.71
19.89
20.96
12.13
12.89
13.89
15.31
16.44
17.28
20.79
22.53
Earnings per share
1.62
1.91
(0.09)
1.97
2.92
3.31
2.12
1.51
1.20
1.42
2.12
0.98
3.41
2.33
3.98
4.13
FCF per share
2.07
1.66
0.81
1.72
3.09
2.97
2.81
1.52
1.18
2.01
2.21
2.83
2.75
2.60
4.26
3.36
Dividends per share
- -
- -
- -
- -
- -
0.30
0.46
0.53
0.40
0.46
0.53
0.60
0.66
0.72
0.78
0.82
CAPEX per share
0.39
0.42
0.37
0.35
0.54
0.56
0.57
0.62
0.29
0.43
0.55
0.55
0.50
0.39
0.62
0.96
Book Value per sh.
8.21
7.05
7.24
9.30
12.41
14.89
15.50
15.91
12.51
13.02
15.00
14.23
15.12
15.77
17.73
17.45
Comm.Shares outs.
394
363
346
347
347
348
341
333
333
326
322
321
314
309
304
304
Avg. annual P/E ratio
15.8
11.3
(173.3)
11.7
10.3
8.6
15.7
26.8
32.8
30.4
27.9
68.4
21.9
39.6
36.2
32.4
P/E to S&P500
0.9
0.5
(2.4)
0.6
0.6
0.6
0.9
1.5
1.6
1.4
1.2
2.7
0.9
1.0
1.2
1.5
Avg. annual div. yield
- -
- -
- -
- -
- -
1.0%
1.4%
1.3%
1.0%
1.1%
0.9%
0.9%
0.9%
0.8%
0.5%
0.6%
Revenue (m)
5,420
5,774
4,481
5,444
6,615
6,858
6,782
6,981
4,038
4,202
4,472
4,914
5,163
5,339
6,319
6,848
Operating margin
10.8%
13.8%
1.0%
10.4%
16.2%
16.3%
14.0%
11.9%
12.9%
14.6%
18.8%
18.9%
18.2%
15.8%
21.3%
23.6%
Depreciation (m)
191
201
162
202
253
301
372
384
253
246
212
210
238
308
321
317
Net profit (m)
638
693
(31)
684
1,012
1,153
724
504
401
462
684
316
1,071
719
1,210
1,254
Income tax rate
4.8%
15.0%
542.9%
1.2%
1.9%
(10.5)%
15.7%
22.0%
8.8%
15.1%
14.8%
66.6%
(16.5)%
14.6%
11.0%
16.6%
Net profit margin
11.8%
12.0%
(0.7)%
12.6%
15.3%
16.8%
10.7%
7.2%
9.9%
11.0%
15.3%
6.4%
20.7%
13.5%
19.1%
18.3%
Working capital (m)
2,008
1,883
2,838
3,086
3,732
2,736
3,381
3,798
2,710
2,690
2,906
2,677
1,109
1,948
2,091
1,917
Long-term debt (m)
2,087
2,125
2,904
2,190
1,932
2,112
2,699
2,762
1,655
1,912
1,801
1,799
1,791
2,284
2,729
2,733
Equity (m)
3,234
2,559
2,506
3,228
4,308
5,182
5,286
5,298
4,167
4,243
4,831
4,567
4,748
4,873
5,389
5,305
ROIC
10.8%
11.3%
(6.5)%
11.8%
15.2%
14.6%
9.0%
6.5%
7.1%
7.6%
10.5%
4.6%
15.7%
9.6%
14.2%
15.3%
Return on capital
8.9%
11.0%
1.2%
8.1%
12.4%
10.9%
9.0%
7.0%
6.8%
7.9%
10.5%
12.0%
10.5%
9.6%
13.5%
15.1%
Return on equity
19.7%
27.1%
(1.2)%
21.2%
23.5%
22.3%
13.7%
9.5%
9.6%
10.9%
14.2%
6.9%
22.6%
14.8%
22.5%
23.6%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
91.0%
78.5%
65.1%
66.8%
67.5%
75.1%
39.6%
80.8%
69.1%
80.5%
80.1%
Div.&Repurch./FCF
192.5%
131.2%
- -
18.8%
18.0%
17.0%
110.3%
74.3%
101.8%
89.3%
51.1%
67.4%
107.4%
78.7%
79.0%
136.0%
Capital Structure
21 Dec · 2022 | Q4
All numbers in millions
Total liabilities
$ 5,227
Total assets
$ 10,532
Long-term debt
$ 2,733
Cash and equiv.
$ 1,053
Goodwill
$ 3,952
Retained earnings
$ 324
Common stock
296
Enterprise Value
$ 47,775
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
1,599
1,575
1,053
Receivables
1,038
1,172
1,405
Inventory
720
830
1,038
Other
58
265
(106)
Current assets
3,415
3,799
3,778
Acc. Payable
354
446
580
Debt due
75
- -
36
Other
1,038
1,262
1,245
Current liabilities
1,467
1,708
1,861
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
8.37%
8.80%
1.82%
Cash flow
(21.22)%
7.04%
6.86%
Earnings
3.64%
69.50%
26.29%
Dividends
5.93%
6.96%
6.08%
Book value
(1.56)%
3.91%
0.52%
Insider Trading
Type
Shares
Date
Ancher-Jensen Henrik
Sale
29,500
12/14/22
Grau Dominique
Sale
4,000
12/13/22
Mcdonnell Padraig
Sale
672
12/13/22
Koh Boon Hwee
Sale
13,000
12/06/22
Thaysen Jacob
Sale
3,235
12/01/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
1,357
1,238
1,261
1,483
5,339
2021
1,548
1,525
1,586
1,660
6,319
2022
1,674
1,607
1,718
1,849
6,848
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.64
0.33
0.64
0.72
2.33
2021
0.95
0.71
0.87
1.45
3.98
2022
0.93
0.90
1.08
1.21
4.13
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.18
0.18
0.18
0.18
0.72
2021
0.19
0.19
0.19
0.19
0.78
2022
0.21
0.21
0.20
0.20
0.82
Company Description
Sector:
Healthcare
Industry:
Diagnostics & Research
CEO:
Mr. Michael McMullen
Full-time employees:
18,100
City:
Santa Clara
Address:
5301 Stevens Creek Blvd
IPO:
Nov 18, 1999
Website:
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.